EUVIMEDEUVIMED entdecken
Open Access

EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells

Jiahui Hou, Tamami Uejima, Miho Tanaka, You Lee Son, Kazuharu Hanada, Mutsuko Kukimoto-Niino, Shigeru Yamaguchi, Shigeru Hashimoto, Shigeyuki Yokoyama, Toshitada Takemori, Takashi Saito, Mikako Shirouzu und 1 weitere

Neuro-Oncology · 07.03.2025 · 27 (3) · 682-694

DOI: 10.1093/neuonc/noae226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 29.10.2024. Verfasst von Jiahui Hou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Immunoconjugates, Neoplastic Stem Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AMED, RIKEN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The discovery of glioblastoma (GBM)-initiating cells (GICs) has impacted GBM research. These cells are not only tumorigenic but also exhibit resistance to radiotherapy and chemotherapy. Therefore, it is crucial to characterize GICs thoroughly and identify new therapeutic targets. In a previous study, we successfully identified epithelial-V–like antigen 1 (EVA1) as a novel functional factor specific to GICs.

Methods

Hybridoma cells were generated by immunizing BALB/c mice with EVA1-Fc fusion protein. The reactivity of the supernatant from these hybridoma cells was examined using EVA1-overexpressing cells and GICs. Candidate antibodies were further selected using Biacore surface plasmon resonance analysis and 2 cytotoxicity assays—antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Among the antibodies, the cytotoxicity of the B2E5-antibody drug conjugate (B2E5-ADC) was evaluated by both adding it to cultured GICs and injecting it into GIC tumor-bearing brains.

Results

B2E5 demonstrated a high affinity for human EVA1 and effectively killed both EVA1-expressing cell lines and GICs in culture through ADCC and CDC. B2E5-ADC also exhibited strong cytotoxicity to GICs in culture and prevented their tumorigenesis in the brain when administered intracranially to the tumor-bearing brain.

Conclusion

Our data indicate that B2E5-ADC is a new and promising therapeutic strategy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsImmunoconjugatesNeoplastic Stem CellsAnimalsHumansMiceMice, Inbred BALB CAntibody-Dependent Cell CytotoxicityXenograft Model Antitumor AssaysTumor Cells, CulturedMice, NudeCell Line, Tumor

Stichwörter der Autor:innen

ADCB2E5EVA1GBM-initiating cellglioblastoma

Substanzen

Immunoconjugates

Autor:innen und Institutionen

  • Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan.
  • Drug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
  • Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan.
  • Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Crystallographic Drug Discovery Platform Unit, RIKEN Program for Drug Discovery and Medical Technology Platforms, Yokohama, Japan.

ORCID-Profile: Toru Kondo

Förderung

  • AMED
  • RIKEN

Zitieren

APA

Hou, J., Uejima, T., Tanaka, M., Son, Y. L., Hanada, K., Kukimoto-Niino, M., Yamaguchi, S., Hashimoto, S., Yokoyama, S., Takemori, T., Saito, T., Shirouzu, M., & Kondo, T. (2025). EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells. Neuro-Oncology, 27(3), 682-694. https://doi.org/10.1093/neuonc/noae226

Vancouver

Hou J, Uejima T, Tanaka M, Son YL, Hanada K, Kukimoto-Niino M, et al. EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells. Neuro-Oncology. 2025;27(3):682-694. doi:10.1093/neuonc/noae226

BibTeX
@article{Hou2025,
  author = {Hou, Jiahui and Uejima, Tamami and Tanaka, Miho and Son, You Lee and Hanada, Kazuharu and Kukimoto-Niino, Mutsuko and Yamaguchi, Shigeru and Hashimoto, Shigeru and Yokoyama, Shigeyuki and Takemori, Toshitada and Saito, Takashi and Shirouzu, Mikako and Kondo, Toru},
  title = {EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {682--694},
  doi = {10.1093/neuonc/noae226}
}
Kostenlos starten →